Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval to market its KRAS G12C inhibitor, ...

1Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York. 2David M. Rubenstein Center for Pancreatic Cancer, Memorial Sloan Kettering ...

Two notable developments exemplify this commitment: the production of the AK-203 assault rifle in Uttar Pradesh and the establishment of the KRAS missile facility in Hyderabad. The AK-203, a ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of Alterome ...

“We look forward to presenting an update to our growing body of preclinical and clinical data that demonstrate the potential of KO-2806 as a companion therapeutic to augment the antitumor activities ...